Pharmacy Medical Benefit Updates Effective 1/1/2027

Effective January 1, 2027, we are changing some of our preferred products under the medical benefit.

- For Denosumabs, the preferred products will be Bildyos/Bilprevda and Enoby/Xtrenbo for all lines of business.
- For Infliximabs, the preferred products will be Avsola and Renflexis for Community Care and Medicare lines of business. This update does not apply to Medicaid ACO.
- For Long-Acting GCSF, the preferred products will be Udenyca and Fulphila for all lines of business.
- For Trastuzumabs, the preferred products will be Ogivri, Ontruzant, and Trazimera for all lines of business.
- For Viscosupplements, the preferred products will be Durolane, Synvisc, and Synvisc-One for Community Care and Medicaid ACO lines of business. This update does not apply to Medicare.
- For Tocilizumabs, the preferred products will be Tyenne and Avtozma for Community Care and Medicare lines of business. This update does not apply to Medicaid ACO.
- For Eculizumab, the preferred products will be Epysqli for Community Care and Medicare lines of business. This update does not apply to Medicaid ACO.
- For Ustekinumabs, the preferred products will be Starjemza, Yesintek, and Steqeyma for Medicare lines of business. This update does not apply to Community Care or Medicaid ACO.

These changes apply to new starts only for Medicare and applies to renewal/continuation for Community Care and Medicaid ACO members. Community Care and Medicaid ACO members will be able to stay on their current drug as long as their approval period. Upon renewal, they will be required to switch to the new preferred alternative.

- Effective January 1, 2027, the following drugs will now require prior authorization for Medicaid ACO lines of business: Fulphila, Neulasta, and Nyvepria.
- Effective January 1, 2027, the following drugs will be removed from prior authorization for Medicaid ACO lines of business: Rolvedon.
- Effective January 1, 2027, prior authorization will be added to all docetaxel products for all lines of business.